These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34407176)

  • 41. Promoting access to COVID-19 convalescent plasma in low- and middle-income countries.
    Bloch EM; Goel R; Montemayor C; Cohn C; Tobian AAR
    Transfus Apher Sci; 2021 Feb; 60(1):102957. PubMed ID: 32972861
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Seroprevalence of SARS-CoV-2 among potential convalescent plasma donors and analysis of their deferral pattern: Experience from tertiary care hospital in western India.
    Jain R; Mallya MV; Amoncar S; Palyekar S; Adsul HP; Kumar R; Chawla S
    Transfus Clin Biol; 2022 Feb; 29(1):60-64. PubMed ID: 34302953
    [TBL] [Abstract][Full Text] [Related]  

  • 44. COVID-19 antibody donation using immunoadsorption: Report of two cases.
    Rothenburg J; Rink-Baron S; Mueller L; Ostermann PN; Fischer J; Stegbauer J; Moldenhauer A
    Transfus Apher Sci; 2021 Oct; 60(5):103193. PubMed ID: 34147358
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Presence and short-term persistence of SARS-CoV-2 neutralizing antibodies in COVID-19 convalescent plasma donors.
    Annen K; Morrison TE; DomBourian MG; McCarthy MK; Huey L; Merkel PA; Andersen G; Schwartz E; Knight V
    Transfusion; 2021 Apr; 61(4):1148-1159. PubMed ID: 33452828
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Analysis of responses of the health care workers recovered from COVID-19 on convalescent plasma donation by apheresis: A single-center survey study.
    Sahu A; Prakash S; Singh AK; Mukherjee S
    J Clin Apher; 2022 Jun; 37(3):273-280. PubMed ID: 35119768
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Analysis of 52 240 source plasma donors of convalescent COVID-19 plasma: Sex, ethnicity, and age association with initial antibody levels and rate of dissipation.
    Schmidt AE; Vogel P; Chastain CA; Barnes T; Roth NJ; Simon TL
    J Clin Apher; 2022 Oct; 37(5):449-459. PubMed ID: 35815776
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The safety of COVID-19 convalescent plasma donation: A multi-institutional donor hemovigilance study.
    Cho JH; Rajbhandary S; van Buren NL; Fung MK; Al-Ghafry M; Fridey JL; Dy BA; Ziman A; Schreiber GB; Gammon RR; Reik R; Stubbs JR; van Buskirk CM; Kamel H; Townsend MJ; Zeller MP; Gottschall JL
    Transfusion; 2021 Sep; 61(9):2668-2676. PubMed ID: 34227689
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Regulatory consideration on preparation and clinical use of COVID-19 convalescent plasma.
    Yılmaz S; Ertuğrul Örüç N; Özcebe Oİ; Azap A; Çetin AT; Yenicesu İ; Öztürk A; Gündüz M; Tekin A
    Transfus Apher Sci; 2020 Oct; 59(5):102846. PubMed ID: 32593519
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
    Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
    Trials; 2021 May; 22(1):342. PubMed ID: 34001174
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Donor tolerability of convalescent plasma donation.
    He R; Lin H; Xie S; Lv Q; Kong Y; Li L; Xu H; Wang J; Li W; Fang P; Wu Y; Liu Z
    J Clin Apher; 2021 Jun; 36(3):429-436. PubMed ID: 33587767
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Limited Correlation between SARS-CoV-2 Serologic Assays for Identification of High-Titer COVID-19 Convalescent Plasma Using FDA Thresholds.
    Larkey NE; Ewaisha R; Lasho MA; Roforth MM; Granger D; Jerde CR; Wu L; Gorsh A; Klassen SA; Senefeld JW; Joyner MJ; Baumann NA; Theel ES; Mills JR
    Microbiol Spectr; 2022 Aug; 10(4):e0115422. PubMed ID: 35862939
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Regulatory challenges of convalescent plasma collection during the evolving stages of COVID-19 pandemic in the United States.
    Hassan S; West KA; Conry-Cantilena K; De Giorgi V
    Transfusion; 2022 Feb; 62(2):483-492. PubMed ID: 34778974
    [No Abstract]   [Full Text] [Related]  

  • 54. Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19.
    Accorsi P; Berti P; de Angelis V; De Silvestro G; Mascaretti L; Ostuni A;
    Transfus Apher Sci; 2020 Aug; 59(4):102817. PubMed ID: 32532691
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients.
    Franchini M; Focosi D; Percivalle E; Beccaria M; Garuti M; Arar O; Pecoriello A; Spreafico F; Greco G; Bertacco S; Ghirardini M; Santini T; Schiavulli M; Stefania M; Gagliardo T; Sammartino JC; Ferrari A; Zani M; Ballotari A; Glingani C; Baldanti F
    Viruses; 2022 Jun; 14(7):. PubMed ID: 35891421
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan.
    Li C; Yu D; Wu X; Liang H; Zhou Z; Xie Y; Li T; Wu J; Lu F; Feng L; Mao M; Lin L; Guo H; Yue S; Wang F; Peng Y; Hu Y; Wang Z; Yu J; Zhang Y; Lu J; Ning H; Yang H; Fu D; He Y; Zhou D; Du T; Duan K; Dong D; Deng K; Zou X; Zhang Y; Zhou R; Gao Y; Zhang X; Yang X
    Nat Commun; 2021 Jul; 12(1):4144. PubMed ID: 34230476
    [TBL] [Abstract][Full Text] [Related]  

  • 57. How do I implement an outpatient program for the administration of convalescent plasma for COVID-19?
    Bloch EM; Tobian AAR; Shoham S; Hanley DF; Gniadek TJ; Cachay ER; Meisenberg BR; Kafka K; Marshall C; Heath SL; Shenoy A; Paxton JH; Levine A; Forthal D; Fukuta Y; Huaman MA; Ziman A; Adamski J; Gerber J; Cruser D; Kassaye SG; Mosnaim GS; Patel B; Metcalf RA; Anjan S; Reisler RB; Yarava A; Lane K; McBee N; Gawad A; Raval JS; Zand M; Abinante M; Broderick PB; Casadevall A; Sullivan D; Gebo KA
    Transfusion; 2022 May; 62(5):933-941. PubMed ID: 35352362
    [TBL] [Abstract][Full Text] [Related]  

  • 58. COVID-19 convalescent plasma.
    Tobian AAR; Cohn CS; Shaz BH
    Blood; 2022 Jul; 140(3):196-207. PubMed ID: 34695186
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: A rousing message of clinical benefit to both donors and recipients alike.
    Seghatchian J; Lanza F
    Transfus Apher Sci; 2020 Jun; 59(3):102794. PubMed ID: 32448638
    [No Abstract]   [Full Text] [Related]  

  • 60. Demographics of first-time donors returning for donation during the pandemic: COVID-19 convalescent plasma versus standard blood product donors.
    Van Buren NL; Rajbhandary S; Reynolds V; Gorlin JB; Stramer SL; Notari EP; Conti G; Katz L; Stubbs JR; van Buskirk CM; Kuttner K; Smith DL; Ngamsuntikul SG; Pandey S; Ward DC; Ziman A; Hiskey M; Townsend M; Sachais BS
    Transfusion; 2023 Mar; 63(3):552-563. PubMed ID: 36550639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.